Gene Expression Profiles in Parkinson Disease Prefrontal Cortex Implicate FOXO1 and Genes under Its Transcriptional Regulation

Parkinson disease (PD) is a complex neurodegenerative disorder with largely unknown genetic mechanisms. While the degeneration of dopaminergic neurons in PD mainly takes place in the substantia nigra pars compacta (SN) region, other brain areas, including the prefrontal cortex, develop Lewy bodies, the neuropathological hallmark of PD. We generated and analyzed expression data from the prefrontal cortex Brodmann Area 9 (BA9) of 27 PD and 26 control samples using the 44K One-Color Agilent 60-mer Whole Human Genome Microarray. All samples were male, without significant Alzheimer disease pathology and with extensive pathological annotation available. 507 of the 39,122 analyzed expression probes were different between PD and control samples at false discovery rate (FDR) of 5%. One of the genes with significantly increased expression in PD was the forkhead box O1 (FOXO1) transcription factor. Notably, genes carrying the FoxO1 binding site were significantly enriched in the FDR–significant group of genes (177 genes covered by 189 probes), suggesting a role for FoxO1 upstream of the observed expression changes. Single-nucleotide polymorphisms (SNPs) selected from a recent meta-analysis of PD genome-wide association studies (GWAS) were successfully genotyped in 50 out of the 53 microarray brains, allowing a targeted expression–SNP (eSNP) analysis for 52 SNPs associated with PD affection at genome-wide significance and the 189 probes from FoxO1 regulated genes. A significant association was observed between a SNP in the cyclin G associated kinase (GAK) gene and a probe in the spermine oxidase (SMOX) gene. Further examination of the FOXO1 region in a meta-analysis of six available GWAS showed two SNPs significantly associated with age at onset of PD. These results implicate FOXO1 as a PD–relevant gene and warrant further functional analyses of its transcriptional regulatory mechanisms.

[1]  Eden R Martin,et al.  Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2 , 2012, Annals of neurology.

[2]  H. Kim,et al.  Silent Information Regulator 2 (Sir2) and Forkhead Box O (FOXO) Complement Mitochondrial Dysfunction and Dopaminergic Neuron Loss in Drosophila PTEN-induced Kinase 1 (PINK1) Null Mutant* , 2012, The Journal of Biological Chemistry.

[3]  N. Hattori,et al.  The Nitric Oxide-Cyclic GMP Pathway Regulates FoxO and Alters Dopaminergic Neuron Survival in Drosophila , 2012, PloS one.

[4]  T. Iwatsubo,et al.  Phosphorylation of α-Synuclein Protein at Ser-129 Reduces Neuronal Dysfunction by Lowering Its Membrane Binding Property in Caenorhabditis elegans* , 2012, The Journal of Biological Chemistry.

[5]  Zhen Yan,et al.  Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells , 2012, Nature Communications.

[6]  N. Belluardo,et al.  Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease , 2012, Cellular and Molecular Life Sciences.

[7]  P. Mariottini,et al.  Spermine oxidase: ten years after , 2012, Amino Acids.

[8]  R. Morishita,et al.  Experimental and clinical application of plasmid DNA in the field of central nervous diseases. , 2011, Current gene therapy.

[9]  M. Fendt,et al.  Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages , 2011, Neurobiology of Disease.

[10]  A. Goldberg,et al.  Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal–lysosomal pathway , 2011, Proceedings of the National Academy of Sciences.

[11]  G. Hu,et al.  Novel role of aquaporin‐4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson’s disease , 2011, Aging cell.

[12]  D. Hernandez,et al.  Genome-wide association study confirms extant PD risk loci among the Dutch , 2011, European Journal of Human Genetics.

[13]  M. Elstner,et al.  Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death , 2011, Acta Neuropathologica.

[14]  S. Lindquist,et al.  Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. , 2011, Human molecular genetics.

[15]  Margaret A. Pericak-Vance,et al.  Identifying Consensus Disease Pathways in Parkinson's Disease Using an Integrative Systems Biology Approach , 2011, PloS one.

[16]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[17]  Beate Ritz,et al.  Replication of GWAS Associations for GAK and MAPT in Parkinson's Disease , 2010, Annals of human genetics.

[18]  I. Ferrer,et al.  Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease , 2011, Journal of Neural Transmission.

[19]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[20]  Z. Salehi,et al.  Expression of hepatocyte growth factor in the serum and cerebrospinal fluid of patients with Parkinson’s disease , 2010, Journal of Clinical Neuroscience.

[21]  Richard H. Myers,et al.  Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease , 2010, Experimental Neurology.

[22]  Manuel B. Graeber,et al.  PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.

[23]  David S. Park,et al.  Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. , 2010, Human molecular genetics.

[24]  M. Nalls,et al.  Genetic variability at the PARK16 locus , 2010, European Journal of Human Genetics.

[25]  J. Nutt,et al.  Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.

[26]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[27]  P. Calabresi,et al.  A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice , 2010, PloS one.

[28]  Aj Lees,et al.  Parkinson's disease (vol 373, pg 2055, 2009) , 2009 .

[29]  Hyoung-Gon Lee,et al.  Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease , 2009, Molecular Neurodegeneration.

[30]  F. Benes,et al.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. , 2009, Brain : a journal of neurology.

[31]  J. Dalley,et al.  Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF , 2009, Proceedings of the National Academy of Sciences.

[32]  H. Shill,et al.  Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.

[33]  D. Stephan,et al.  Genetic control of human brain transcript expression in Alzheimer disease. , 2009, American journal of human genetics.

[34]  T. Mak,et al.  FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation , 2009, Proceedings of the National Academy of Sciences.

[35]  Christine A. Wells,et al.  A Cross-Study Transcriptional Analysis of Parkinson's Disease , 2009, PloS one.

[36]  Audrey Kauffmann,et al.  Bioinformatics Applications Note Arrayqualitymetrics—a Bioconductor Package for Quality Assessment of Microarray Data , 2022 .

[37]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[38]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[39]  K. Shianna,et al.  Tissue-Specific Genetic Control of Splicing: Implications for the Study of Complex Traits , 2008, PLoS biology.

[40]  Eden R Martin,et al.  A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms , 2008, Genetic epidemiology.

[41]  Srichand Jasti,et al.  SAS Macros for Testing Statistical Mediation in Data With Binary Mediators or Outcomes , 2008, Nursing research.

[42]  J. Cooper,et al.  Distinct Roles for Arp2/3 Regulators in Actin Assembly and Endocytosis , 2008, PLoS biology.

[43]  D. Connor,et al.  The Sun Health Research Institute Brain Donation Program: Description and Eexperience, 1987–2007 , 2007, Cell and Tissue Banking.

[44]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[45]  Hitoshi Takahashi,et al.  The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates , 2007, Neuropathology : official journal of the Japanese Society of Neuropathology.

[46]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[47]  Eden R Martin,et al.  Family‐based case–control study of MAOA and MAOB polymorphisms in Parkinson disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[48]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[49]  Mariza de Andrade,et al.  High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.

[50]  F. Middleton,et al.  Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[51]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[52]  Charles Duyckaerts,et al.  Dopamine depletion impairs precursor cell proliferation in Parkinson disease , 2004, Nature Neuroscience.

[53]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[54]  S. West,et al.  A comparison of methods to test mediation and other intervening variable effects. , 2002, Psychological methods.

[55]  J. Jankovic,et al.  Variability and validity of polymorphism association studies in Parkinson’s disease , 2000, Neurology.

[56]  K. Honda,et al.  Detection and analysis of four polymorphic markers at the human monoamine oxidase (MAO) gene in Japanese controls and patients with Parkinson's disease. , 1998, Biochemical and biophysical research communications.

[57]  M F Huque,et al.  Some comments on frequently used multiple endpoint adjustment methods in clinical trials. , 1997, Statistics in medicine.

[58]  Paul J. Harrison,et al.  The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins , 1995, Neuroscience Letters.

[59]  C. Markham,et al.  Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.

[60]  D. A. Kenny,et al.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. , 1986, Journal of personality and social psychology.